Investor Presentaiton

Liwen RF Ablation System 屈启明医疗® VENUSMEDTECH In Sep 2021, Venus Medtech entered into share transfer agreement to acquire the shares of Hangzhou Nuocheng Medical Technology Co.,Ltd to obtain its Liwen RF ablation system for treatment of hypertrophic cardiomyopathy. Feature Global novel HCM treatment: echocardiography- guided percutaneous intramyocardial septal radiofrequency ablation Compared with surgical myectomy and alcohol septal ablation, less invasive, short recovery, less damage to conduction system, lower recurrence rate and mortality rate Controlled ablation power and range, complete ablation 22 22

View entire presentation